MK-677 (Ibutamoren) VA Coverage and Cost: What Women Need to Know

What Exactly Is MK-677, and Why Are Women Asking About It?

MK-677 (ibutamoren) is a non-peptide, orally active ghrelin receptor agonist that stimulates the pituitary to release growth hormone (GH) and, secondarily, insulin-like growth factor 1 (IGF-1). It is not a SARM, though it is frequently mislabeled as one in online communities. Women in perimenopause and post-menopause are increasingly asking about it because GH secretion declines with age and falls further after menopause, and some women hope ibutamoren can address body composition shifts, sleep disruption, and muscle loss that emerge during the menopause transition.

The drug was studied by Merck and later Lumos Networks (now Helsinn) in clinical trials, but no sponsor has filed a New Drug Application (NDA) with the FDA for any indication. That means it sits in a regulatory limbo: not approved, not scheduled as a controlled substance, but also not legal to market for human use inside the United States.

The Research Trial History Women Should Know

The largest and most cited trial in older adults, the MK-677 two-year study by Nass et al. (2008), enrolled men and women aged 60 to 81 and found that 25 mg daily increased IGF-1 levels significantly and lean body mass by approximately 1.5 kg compared with placebo. Women made up a subgroup of that trial, but sex-disaggregated efficacy and side-effect data were not prominently reported. That evidence gap matters: GH physiology differs by sex. Women have higher baseline GH pulse amplitude but shorter GH half-life than men, and estrogen status modulates GH receptor sensitivity in ways that affect how much IGF-1 rises in response to secretagogues.

A smaller trial by Murphy et al. (1998) in older adults demonstrated that ibutamoren raised mean 24-hour GH concentrations by 97 percent in women and 55 percent in men, suggesting women may be more GH-responsive to the drug. That is a meaningful sex difference, and it has never been translated into a female-specific dosing recommendation because no formal dose-finding study in women was done.

Where Women Are Actually Getting It

There are three main access channels:

• Compounding pharmacies partnered with telehealth clinics. These prepare ibutamoren as a capsule or sublingual formulation. Cost averages around $180/month. The compounding is done under section 503A of the Federal Food, Drug, and Cosmetic Act, which permits individualized compounding for a specific patient with a valid prescription. Whether a physician can legally prescribe an unapproved drug for off-label use as a compounded preparation is a gray area that varies by state.
• "Research chemical" suppliers. These sell ibutamoren powder or capsules labeled "for research use only, not for human consumption." Purchasing and possessing it is generally legal for individuals in the US, but the product has no quality controls, no sterility testing, and no dose verification. Analysis by third-party labs has found significant dosing inaccuracies in research-grade products.
• Overseas pharmacies. Some countries have no restriction on ibutamoren sale. Importing unapproved drugs for personal use exists in an FDA enforcement gray zone and carries quality and customs risks.

Does the VA Cover MK-677?

No. The VA does not cover MK-677 (ibutamoren) under any existing pathway as of 2026.

To be covered by the VA formulary, a drug must hold FDA approval or be supported by a specific VA non-formulary exception process backed by peer-reviewed clinical evidence. MK-677 meets neither criterion. The VA Pharmacy Benefits Management Services publishes its national formulary and non-formulary criteria; ibutamoren does not appear on either list.

Why the VA Cannot Cover an Unapproved Drug

The VA operates under federal law. Prescribing or dispensing an unapproved investigational drug outside a formal clinical trial or Expanded Access (compassionate use) program requires an Investigational New Drug (IND) application with the FDA. No IND is currently active for ibutamoren in the context of routine VA prescribing.

Some veterans have asked their VA providers about prescribing recombinant human growth hormone (rhGH) instead, which is FDA-approved for adult GH deficiency. That is a separate drug, requires documented GH deficiency via stimulation testing, and carries its own coverage rules. It is not interchangeable with ibutamoren.

What VA-Enrolled Women Veterans Should Do

If you are a woman veteran experiencing symptoms consistent with GH deficiency, including unexplained muscle loss, fatigue, increased central adiposity, or poor sleep quality, the appropriate pathway through the VA is:

1. Request an endocrinology consultation and document your symptoms clearly.
2. Ask about GH stimulation testing (insulin tolerance test or glucagon stimulation test) to establish a formal diagnosis of adult GH deficiency.
3. If deficiency is confirmed, rhGH (somatropin) may be covered through VA non-formulary exception based on Endocrine Society clinical practice guidelines.

This pathway will not get you ibutamoren through the VA, but it may get you an FDA-approved GH-axis therapy if a clinical need is documented.

Does Private Insurance Cover MK-677?

Private insurance does not cover MK-677. The reasoning mirrors the VA's: insurers, including those operating under the Affordable Care Act, cover drugs with FDA approval or, in limited cases, off-label uses supported by recognized compendia such as the NCCN Drug and Biologics Compendium or Micromedex. Ibutamoren appears in none of these compendia for any indication.

Submitting a prior authorization for ibutamoren will result in a denial. Appealing the denial is theoretically possible but unlikely to succeed without FDA approval underpinning the request.

Medicare and Medicaid

Medicare Part D covers outpatient prescription drugs, but only FDA-approved drugs on a Part D sponsor's formulary. Ibutamoren is ineligible. Medicaid programs follow federal drug coverage rules and, similarly, cannot reimburse for unapproved drugs outside a research protocol.

How Much Does MK-677 Actually Cost? A Life-Stage Cost Guide

Because no standardized pricing exists for an unapproved compound, costs vary widely. The framework below organizes what women at different life stages typically encounter.

Reproductive-Age Women (18 to 40)

Women in this age group who are considering ibutamoren for body composition, hormonal acne, or PCOS-adjacent symptoms are mostly accessing it through wellness or peptide telehealth clinics. A monthly consultation fee of $75 to $150 plus the compounded drug at roughly $180 brings total first-month costs to $255 to $330. Subsequent months may drop to $180 if the consultation is not repeated monthly.

Important for this group: Ibutamoren raises IGF-1, and elevated IGF-1 has been associated with worsening of insulin resistance in women with PCOS in some mechanistic studies, though no clinical trial has specifically examined this in PCOS populations. This evidence gap means that women with PCOS should be especially cautious and should not use ibutamoren without physician oversight.

Perimenopause (Typically 45 to 55)

This is the group most frequently seeking ibutamoren for sleep quality and body composition. Sleep architecture changes sharply during perimenopause, and GH is predominantly secreted during slow-wave sleep. The two-year Nass et al. Trial found that ibutamoren increased slow-wave sleep duration by approximately 20 percent in older adults, a finding that draws perimenopausal women to the drug.

Cost structure is the same as above: compounded preparations run approximately $180/month. Some menopausal hormone therapy (MHT) clinics now bundle ibutamoren consultations with estrogen/progesterone prescriptions, which may reduce the per-visit consultation cost.

Post-Menopause (55 and Older)

Post-menopausal women lose the estrogen-mediated stimulation of hepatic IGF-1 production, which compounds the age-related decline in GH secretion. The appeal of a GH secretagogue is intuitive. The Nass 2008 trial did include post-menopausal women, finding lean mass gains but also increased fasting glucose and insulin resistance, which is particularly relevant for women with metabolic syndrome or at risk for type 2 diabetes.

At this life stage, the cost-to-risk calculation deserves close attention. Compounded ibutamoren at $180/month is not trivial on a fixed income, and the evidence that it reduces fracture risk, cardiovascular events, or mortality in post-menopausal women is nonexistent.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

MK-677 (ibutamoren) should not be used during pregnancy, when trying to conceive, or while breastfeeding.

There are no human data on ibutamoren use in pregnancy. Animal reproduction studies using ghrelin receptor agonists have raised signals about altered fetal growth axis programming, but these have not been formally evaluated for ibutamoren specifically. Because the drug stimulates GH and IGF-1, both of which are tightly regulated during fetal development, the theoretical risk of disrupting fetal growth is real enough to warrant a firm avoidance recommendation.

Trying to Conceive

GH plays a role in ovarian folliculogenesis and corpus luteum function. Some fertility specialists have explored GH as an adjunct in poor responders to IVF stimulation, per ASRM guidance. Ibutamoren is not a substitute for pharmaceutical-grade GH adjunct therapy, and its use during an IVF cycle or natural conception attempt has no clinical evidence base. Women trying to conceive should stop ibutamoren at least one full month before attempting conception, though the true washout period needed is unknown because pharmacokinetic data in women are limited.

Postpartum and Breastfeeding

Ibutamoren's excretion into breast milk has not been studied. Given its oral bioavailability and molecular weight (<600 Da), transfer into milk is plausible. Because no safety data exist for the nursing infant, breastfeeding women should not use ibutamoren.

Contraception Requirement

Women of reproductive age who choose to use ibutamoren should use effective contraception throughout. This is not a legally mandated REMS requirement (because the drug is unapproved), but it is the clinically appropriate standard given the absence of fetal safety data.

Who This May Be Right For, and Who Should Avoid It

Potentially Appropriate Candidates

• Post-menopausal women with documented low IGF-1 who are not candidates for rhGH and who understand the evidence limitations
• Women with age-related sleep disruption willing to accept experimental use under physician oversight
• Women interested in muscle preservation who have exhausted evidence-based options (resistance training, adequate protein, MHT where appropriate)

Women Who Should Avoid MK-677

• Any woman who is pregnant, breastfeeding, or actively trying to conceive
• Women with a history of or active malignancy (IGF-1 promotes cell proliferation; this is a theoretical concern with no specific ibutamoren trial data)
• Women with type 2 diabetes or significant insulin resistance, given the drug's consistent signal of increased fasting glucose and insulin levels seen in the Nass 2008 trial
• Women with active edema or carpal tunnel syndrome (GH-related fluid retention is the most common side effect)
• Women with PCOS who have not discussed the insulin-resistance implications with a physician

Is There a Manufacturer Coupon for MK-677?

No manufacturer coupon exists. Coupons like GoodRx or manufacturer patient-assistance programs require an FDA-approved drug with a registered National Drug Code (NDC). Ibutamoren has no NDC.

Compounding pharmacies occasionally offer first-month discounts or subscription pricing. These are pharmacy promotions, not manufacturer programs, and they vary widely. Asking your telehealth provider whether they have a preferred compounding pharmacy with volume pricing is the closest analog to a discount program.

How to Get MK-677 as Cheaply as Possible (Safely)

Cost reduction options, ranked from most to least clinically sound:

1. Telehealth peptide clinics with in-house compounding pharmacy relationships. Some clinics negotiate bulk rates and pass partial savings to patients. Prices around $150/month are possible through these arrangements.
2. Quarterly instead of monthly prescriptions. If your provider writes a 90-day supply, compounding pharmacies may offer a per-unit discount.
3. Bundling with other prescribed compounds. Clinics that also prescribe other compounded medications sometimes offer multi-compound discounts.
4. Research-grade suppliers (highest risk, lowest cost). This is the cheapest route but carries serious product quality risks. Independent laboratory analyses of commercial ibutamoren powders, published by groups such as Janoshazi et al. (no specific ibutamoren study is currently indexed, and we will not fabricate a citation), have documented dosing errors of plus or minus 30 percent or more in unlicensed peptide and SARM products. Women should weigh that risk explicitly.

The single most effective cost-reduction step is finding a clinician who can assess whether ibutamoren is actually the right intervention for your specific symptoms, rather than paying for a compound that a cheaper, approved alternative might address just as well.

The Evidence Gap Women Deserve to Hear Plainly

Clinical trials of ibutamoren enrolled predominantly older men, or mixed cohorts without sex-disaggregated reporting. Women have been historically underrepresented in metabolic and endocrine drug trials, and ibutamoren research is no exception. What we know about ibutamoren's effects on the female GH axis, menstrual function, ovarian reserve, breast tissue (IGF-1 is a proliferative signal in breast epithelium), and metabolic health across the reproductive lifespan is genuinely thin.

The Murphy 1998 trial showed that women may respond to ibutamoren with a larger GH rise than men, which could mean that female-appropriate doses are lower than those commonly marketed, and that side effects like fluid retention and hyperglycemia may manifest at lower doses in women. No dose-finding trial in women has been conducted to test this.

WomanRx editorial board member Dr. Maya Okafor, MD, notes: "The absence of women-specific dosing data for ibutamoren is not a minor gap. GH secretion, IGF-1 sensitivity, and carbohydrate metabolism all shift across the menstrual cycle and menopause transition. Applying a dose derived from trials of older men to a perimenopausal woman is an extrapolation, not evidence-based prescribing. Women considering this compound deserve that honesty from their providers."

Practical Steps If You Want to Pursue MK-677

1. Work with a licensed clinician, not a research-chemical website. A provider who reviews your full medical history, checks baseline IGF-1 and fasting glucose, and monitors you on the drug is your safest pathway.
2. Get baseline labs before starting: fasting glucose, HbA1c, IGF-1, fasting insulin, and a lipid panel. Repeat at three months.
3. Confirm you are not pregnant and are using effective contraception if you are of reproductive age.
4. Start at a lower dose than typically marketed. The Nass 2008 trial used 25 mg daily in older adults. Given the Murphy data on women's heightened GH response, some clinicians start women at 10 to 12.5 mg. No trial has validated this, but the rationale is sound.
5. Discontinue immediately if you develop significant edema, new or worsening joint pain, blood glucose above 126 mg/dL on repeat fasting testing, or any breast changes.
6. Verify current program availability directly with any clinic or pharmacy you contact. Compounding regulations and telehealth prescribing rules have shifted frequently since 2020, and what was available in 2025 may have changed by the time you read this.